本文已被:浏览 916次 下载 526次
投稿时间:2018-11-19 网络发布日期:2019-09-24
投稿时间:2018-11-19 网络发布日期:2019-09-24
中文摘要: 探讨成人急性副鼻窦炎患者应用克拉霉索联合氨溴素(沐舒坦)治疗的临床效果。方法选取2015年1月至2017年1月本院收治的鼻窦炎患者142例,按照治疗方式分为两组各71例。对照组患者应用克拉霉素进行治疗,研究组患者使用克拉霉素联合沐舒坦进行治疗。对比两组患者鼻黏膜纤毛清除率(MCR)、鼻黏膜纤毛输送率(MTR)及临床疗效。结果研究组患者治疗3 d、7 d MCC优于对照组(P<0.01);研究组患者治疗3 d、7 d MTR优于对照组(P<0.01);研究组总有效率为91.5%,优于对照组的78.8%(P<0.05)。结论对成人急性副鼻窦炎患者应用克拉霉素联合沐舒坦治疗,可明显提高患者MCC、MTR的评分,临床效果良好。
中文关键词: 急性副鼻窦炎 克拉霉素 氨溴素,沐舒坦 纤毛清除率;纤毛输送率 不良反应
Abstract:Objective To investigate the clinical effect of clarithromycin combined with ambroxal(mucosolvan) in the treatment of adult acute paranasal sinusitis. Methods A total of 142 patients with nasosinusitis who received treatment from January 2016 to January 2017 were selected and divided into control group and study group according to treatment method (n=71,each).The control group was treated with clarithromycin,while the study group was treated with clarithromycin combined with mucosolvan.The nasal mucociliary clearance rate (MCR),nasal mucociliary transport rate (MTR) and clinical efficacy were compared between the two groups. Results At 3 d and 7 d after the treatment,MCR and MTR in the study group were significantly better than that in the control group (all P<0.05).The total effective rate in study group was significantly better than that in control group (91.5% vs 78.8%,P<0.05). Conclusion The application of Clarithromycin combined with Mucosolvan in the treatment of adult acute paranasal sinusitis can significantly improve the scores of MCC and MTR,and the clinical effect is good.
keywords: Acute paranasal sinusitis Clarithromycin Ambroxal,mucosolvan Mucociliary clearance rate Mucociliary transport rate Adverse reaction
文章编号: 中图分类号:R 765.4+1 文献标志码:B
基金项目:云南省科技厅社会发展科技攻关科研项目
附件
Author Name | Affiliation |
WANG Gui-fang,HUANG Guan-hui,XIE Hong-guan | Department of Otolaryngology,No.926 Hospital of PLA,Honghe,Yunnan 661600,China |
引用文本:
王桂芳,黄观辉,谢红冠.克拉霉素联合盐酸氨溴索治疗成人急性副鼻窦炎[J].中国临床研究,2019,32(9):1252-1254.
王桂芳,黄观辉,谢红冠.克拉霉素联合盐酸氨溴索治疗成人急性副鼻窦炎[J].中国临床研究,2019,32(9):1252-1254.